Terms: = Ovarian cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
14 results:
1. Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study.
El Desoky ES; Taha AF; Mousa HS; Ibrahim A; Saleh MA; Abdelrady MA; Hareedy MS
J Oncol Pharm Pract; 2023 Oct; 29(7):1673-1686. PubMed ID: 36567618
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Mysona D; Dorr K; Ward A; Shaver E; Rungruang B; Ghamande S
Gynecol Oncol; 2023 Jan; 168():114-118. PubMed ID: 36434945
[TBL] [Abstract] [Full Text] [Related]
3. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.
Marchocki Z; Tone A; Virtanen C; de Borja R; Clarke B; Brown T; May T
J Ovarian Res; 2022 May; 15(1):50. PubMed ID: 35501919
[TBL] [Abstract] [Full Text] [Related]
4. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Green ML; Ma SC; Goble S; Giordano H; Maloney L; Simmons AD; Beltman J; Harding TC; Xiao JJ
Cancer Chemother Pharmacol; 2022 May; 89(5):671-682. PubMed ID: 35397664
[TBL] [Abstract] [Full Text] [Related]
5. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in cancer Patients.
Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
[TBL] [Abstract] [Full Text] [Related]
6. Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.
Trousil S; Lee P; Edwards RJ; Maslen L; Lozan-Kuehne JP; Ramaswami R; Aboagye EO; Clarke S; Liddle C; Sharma R
Br J Pharmacol; 2019 Sep; 176(18):3712-3722. PubMed ID: 31236938
[TBL] [Abstract] [Full Text] [Related]
7. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract] [Full Text] [Related]
8. [ovarian Ablation in Breast cancer Patients and the Possibility of Influencing Treatment Side Effects].
Palácová M
Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722
[TBL] [Abstract] [Full Text] [Related]
9. Adjuvant endocrine therapy of premenopausal women with early breast cancer: an overview.
Hubalek M; Brantner C; Marth C
Wien Med Wochenschr; 2010 Apr; 160(7-8):167-73. PubMed ID: 20473727
[TBL] [Abstract] [Full Text] [Related]
10. Cytochrome P450 gene polymorphism and cancer.
Agundez JA
Curr Drug Metab; 2004 Jun; 5(3):211-24. PubMed ID: 15180491
[TBL] [Abstract] [Full Text] [Related]
11. Refinement of an ovarian cancer tumour suppressor gene locus on chromosome arm 22q and mutation analysis of cyp2d6, SREBP2 and NAGA.
Bryan EJ; Thomas NA; Palmer K; Dawson E; Englefield P; Campbell IG
Int J Cancer; 2000 Sep; 87(6):798-802. PubMed ID: 10956388
[TBL] [Abstract] [Full Text] [Related]
12. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Hutson PR; Tutsch KD; Rago R; Arzoomanian R; Alberti D; Pomplun M; Church D; Marnocha R; Cheng AL; Kehrli N; Wilding G
Clin Cancer Res; 1998 Jun; 4(6):1429-36. PubMed ID: 9626459
[TBL] [Abstract] [Full Text] [Related]
13. Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression.
Sarhanis P; Redman C; Perrett C; Brannigan K; Clayton RN; Hand P; Musgrove C; Suarez V; Jones P; Fryer AA; Farrell WE; Strange RC
Br J Cancer; 1996 Dec; 74(11):1757-61. PubMed ID: 8956789
[TBL] [Abstract] [Full Text] [Related]
14. Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and cyp2d, on chromosome 22q.
Bryan EJ; Watson RH; Davis M; Hitchcock A; Foulkes WD; Campbell IG
Cancer Res; 1996 Feb; 56(4):719-21. PubMed ID: 8631002
[TBL] [Abstract] [Full Text] [Related]
